Fig. 3.

Clinical benefit of FIRLs signature for patients with OC. a PCA analysis of high-risk and low-risk groups in the the training set; b Kaplan–Meier survival analysis of high-risk and low-risk groups in the training set; c ROC curve of 1,3,5 year survival prediction in the training set; d A heatmap of 8 FIRLs participating in signature construction in the training set; e PCA analysis of high-risk and low-risk groups in the testing set; f Kaplan–Meier survival analysis of high-risk and low-risk groups in the testing set; g ROC curve of 1,3,5 year survival prediction in the testing set; h A heatmap of 8 FIRLs participating in signature construction in the testing set